Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05351541Phase 1Active Not Recruiting

Psilocybin Therapy for Chronic Low Back Pain

Role: lead

NCT06919640Phase 1Enrolling By Invitation

Psilocybin With Intracranial Neural Sensing

Role: lead

NCT06455293Phase 2Recruiting

Psilocybin Therapy for Depression in Parkinson's Disease

Role: lead

NCT04932434Phase 2Completed

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

Role: lead

All 4 trials loaded